Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 7/20 | 0.36 |
| ▸ | BPTF | Q12830 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.33 |
| ▸ | RBP4 | P02753 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
| ▸ | LPL | P06858 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | BCL9 | O00512 | 1/20 | 0.32 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2524532 | 0.82 | EPHX2 (0.45) | NOTUMBPTFFFAR4EPHX2BCL9 | |
| SCHEMBL902233 | 0.81 | NOTUM (0.35) | NOTUMFFAR4LIPGROCK1LPL | |
| SCHEMBL14905664 | 0.81 | EPHX2 (0.43) | NOTUMBPTFEPHX2 | |
| SCHEMBL14905665 | 0.80 | NOTUM (0.40) | NOTUM | |
| SCHEMBL24846896 | 0.78 | LIPG (0.40) | BPTFFFAR4LIPGROCK1LPL | |
| SCHEMBL30180197 | 0.78 | LIPG (0.40) | BPTFFFAR4LIPGROCK1LPL | |
| SCHEMBL13420961 | 0.78 | NOTUM (0.60) | NOTUM | |
| SCHEMBL26881403 | 0.76 | SETD2 (0.47) | NOTUM | |
| SCHEMBL25966618 | 0.76 | SETD2 (0.47) | NOTUM | |
| SCHEMBL3723644 | 0.75 | HTR6 (0.38) | NOTUMLIPGLPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110251176-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251176-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | PIM1, PIM2, PIM3 | NOTUM 3957/4885BPTF 3786/4885FFAR4 2747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.